ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$18.77 USD
-0.22 (-1.16%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $18.76 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ACAD 18.77 -0.22(-1.16%)
Will ACAD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACAD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACAD
Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ACAD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?
Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue?
Other News for ACAD
Needham healthcare analysts hold analyst/industry conference call
Needham healthcare analysts hold analyst/industry conference call
Oppenheimer Remains a Hold on ACADIA Pharmaceuticals (ACAD)
Needham healthcare analysts hold analyst/industry conference call
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024